Brief: Argenx, Zai Lab Announce Approval Of Efgartigimod Alfa Injection For Generalized Myasthenia Gravis In China
16/07/2024 05:51
July 16 (Reuters) - argenx SE ARGX.BR :
* ARGENX AND ZAI LAB ANNOUNCE APPROVAL OF EFGARTIGIMOD ALFA
INJECTION (SUBCUTANEOUS INJECTION) FOR GENERALIZED MYASTHENIA
GRAVIS IN CHINA
Source text for Eikon: ID:nGNE4Y1Ndv
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles